Grant: Discovery Grants Program - Individual
Université de Montréal
$90,000.00
New methods in peptide mimicry
EF 2009-10
Résumé
Peptides and more importantly their related mimics, both serve as effective drugs in clinic today. Prominent traditional examples include oxytocin, insulin, cyclosporin and salmon calcitonin, which are widely used in childbirth, diabetes, immunosuppression and osteoporosis, respectively. At present more than 40 peptides are marketed worldwide, around 270 peptides are in clinical phase testing, and about 400 are in advanced preclinical phases (Marx, V. "Watching Peptide Drugs Grow Up" Chem. & Eng. News Mar. 14, 2005, Vol 83 (11) pp. 17-24). A new age of peptide-based pharmaceutical agents is emerging from fertile studies in genomics and proteomics. Inherent drawbacks to peptide structures have, however, required development of novel tools for studying peptide interactions and new peptide mimics with improved pharmacological properties to surmount the necessary hurdles to enter into clinic. Such has been the case for new peptide-based drugs, such as the GnRH antagonist Zoladex for treating prostate cancer, which was made more resistant to enzyme metabolism by incorporating an aza-amino acid at the C-terminal residue. Similarly, Symlin a new drug for the treatment of diabetes contains a synthetic analog of a naturally occurring human peptide hormone, amylin. Promising peptide-based drugs for the future include vaccines against various cancers and malaria as well as novel antimicrobial agents to fight organisms exhibiting resistance to present day drugs. The process from peptide to drug is, however, particularly challenging and diagnostic tools for dissecting the native peptide are required to furnish information for recreating elements required for receptor recognition and signal transduction. This proposal focuses on the creation of such tools and their use to construct mimics exhibiting higher potency, enhanced metabolic stability and improved biological availability relative to the native peptide. Because the number of peptides serving as lead structures for drug discovery continues to grow, the proposed research on new strategies for creating peptide mimics is positioned to provide valuable insight and practical leads for the future production of new drugs, biopolymers and materials.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
121839-2009
Name nom
Lubell, William
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
90000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
5
Application title
New methods in peptide mimicry
Keyword
NA
Application summary
Peptides and more importantly their related mimics, both serve as effective drugs in clinic today. Prominent traditional examples include oxytocin, insulin, cyclosporin and salmon calcitonin, which are widely used in childbirth, diabetes, immunosuppression and osteoporosis, respectively. At present more than 40 peptides are marketed worldwide, around 270 peptides are in clinical phase testing, and about 400 are in advanced preclinical phases (Marx, V. "Watching Peptide Drugs Grow Up" Chem. & Eng. News Mar. 14, 2005, Vol 83 (11) pp. 17-24). A new age of peptide-based pharmaceutical agents is emerging from fertile studies in genomics and proteomics. Inherent drawbacks to peptide structures have, however, required development of novel tools for studying peptide interactions and new peptide mimics with improved pharmacological properties to surmount the necessary hurdles to enter into clinic. Such has been the case for new peptide-based drugs, such as the GnRH antagonist Zoladex for treating prostate cancer, which was made more resistant to enzyme metabolism by incorporating an aza-amino acid at the C-terminal residue. Similarly, Symlin a new drug for the treatment of diabetes contains a synthetic analog of a naturally occurring human peptide hormone, amylin. Promising peptide-based drugs for the future include vaccines against various cancers and malaria as well as novel antimicrobial agents to fight organisms exhibiting resistance to present day drugs. The process from peptide to drug is, however, particularly challenging and diagnostic tools for dissecting the native peptide are required to furnish information for recreating elements required for receptor recognition and signal transduction. This proposal focuses on the creation of such tools and their use to construct mimics exhibiting higher potency, enhanced metabolic stability and improved biological availability relative to the native peptide. Because the number of peptides serving as lead structures for drug discovery continues to grow, the proposed research on new strategies for creating peptide mimics is positioned to provide valuable insight and practical leads for the future production of new drugs, biopolymers and materials.